Is aprotinin indicated for reoperative valvular surgery?

Daniel J. Goldstein, Carolyn M. DeRosa, J. Alex Seldomridge, Alan D. Weinberg, Mehmet C. Oz, Craig R. Smith

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and aims of the study: While the hemostatic effect of aprotinin for patients undergoing reoperative coronary bypass is well established, it remains unclear whether these effects extend to patients undergoing reoperative valvular surgery. Methods: We examined our experience with 85 consecutive patients undergoing isolated reoperative valvular surgery with and without use of perioperative aprotinin in order to investigate differences in perioperative blood use, blood loss, bleeding complications, mortality and incidence of myocardial injury. Results: Aprotinin recipients benefitted from a significant reduction in bleeding complications, and a decrease in perioperative and in-hospital mortalities as compared with untreated patients. Anaphylactic reactions and clinically significant thromboembolic events were not observed. There was no difference in the incidence of renal dysfunction or myocardial injury among aprotinin-treated and untreated groups. Conclusions: Our results indicate that aprotinin therapy can be safely administered to patients undergoing reoperative valvular surgery. No increased incidence of anaphylactic reactions, renal dysfunction or perioperative myocardial injury was noted. The observed reductions in bleeding complications and perioperative and in-hospital mortality strongly warrant the evaluation of aprotinin for reoperative valvular surgery in a prospective fashion.

Original languageEnglish (US)
Pages (from-to)88-92
Number of pages5
JournalJournal of Heart Valve Disease
Volume6
Issue number1
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Aprotinin
Anaphylaxis
Hemorrhage
Hospital Mortality
Incidence
Wounds and Injuries
Kidney
Hemostatics
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Goldstein, D. J., DeRosa, C. M., Seldomridge, J. A., Weinberg, A. D., Oz, M. C., & Smith, C. R. (1997). Is aprotinin indicated for reoperative valvular surgery? Journal of Heart Valve Disease, 6(1), 88-92.

Is aprotinin indicated for reoperative valvular surgery? / Goldstein, Daniel J.; DeRosa, Carolyn M.; Seldomridge, J. Alex; Weinberg, Alan D.; Oz, Mehmet C.; Smith, Craig R.

In: Journal of Heart Valve Disease, Vol. 6, No. 1, 01.1997, p. 88-92.

Research output: Contribution to journalArticle

Goldstein, DJ, DeRosa, CM, Seldomridge, JA, Weinberg, AD, Oz, MC & Smith, CR 1997, 'Is aprotinin indicated for reoperative valvular surgery?', Journal of Heart Valve Disease, vol. 6, no. 1, pp. 88-92.
Goldstein DJ, DeRosa CM, Seldomridge JA, Weinberg AD, Oz MC, Smith CR. Is aprotinin indicated for reoperative valvular surgery? Journal of Heart Valve Disease. 1997 Jan;6(1):88-92.
Goldstein, Daniel J. ; DeRosa, Carolyn M. ; Seldomridge, J. Alex ; Weinberg, Alan D. ; Oz, Mehmet C. ; Smith, Craig R. / Is aprotinin indicated for reoperative valvular surgery?. In: Journal of Heart Valve Disease. 1997 ; Vol. 6, No. 1. pp. 88-92.
@article{fd8619f2e114489199d8797f237b5b0d,
title = "Is aprotinin indicated for reoperative valvular surgery?",
abstract = "Background and aims of the study: While the hemostatic effect of aprotinin for patients undergoing reoperative coronary bypass is well established, it remains unclear whether these effects extend to patients undergoing reoperative valvular surgery. Methods: We examined our experience with 85 consecutive patients undergoing isolated reoperative valvular surgery with and without use of perioperative aprotinin in order to investigate differences in perioperative blood use, blood loss, bleeding complications, mortality and incidence of myocardial injury. Results: Aprotinin recipients benefitted from a significant reduction in bleeding complications, and a decrease in perioperative and in-hospital mortalities as compared with untreated patients. Anaphylactic reactions and clinically significant thromboembolic events were not observed. There was no difference in the incidence of renal dysfunction or myocardial injury among aprotinin-treated and untreated groups. Conclusions: Our results indicate that aprotinin therapy can be safely administered to patients undergoing reoperative valvular surgery. No increased incidence of anaphylactic reactions, renal dysfunction or perioperative myocardial injury was noted. The observed reductions in bleeding complications and perioperative and in-hospital mortality strongly warrant the evaluation of aprotinin for reoperative valvular surgery in a prospective fashion.",
author = "Goldstein, {Daniel J.} and DeRosa, {Carolyn M.} and Seldomridge, {J. Alex} and Weinberg, {Alan D.} and Oz, {Mehmet C.} and Smith, {Craig R.}",
year = "1997",
month = "1",
language = "English (US)",
volume = "6",
pages = "88--92",
journal = "The Journal of heart valve disease",
issn = "0966-8519",
publisher = "ICR Publishers Ltd",
number = "1",

}

TY - JOUR

T1 - Is aprotinin indicated for reoperative valvular surgery?

AU - Goldstein, Daniel J.

AU - DeRosa, Carolyn M.

AU - Seldomridge, J. Alex

AU - Weinberg, Alan D.

AU - Oz, Mehmet C.

AU - Smith, Craig R.

PY - 1997/1

Y1 - 1997/1

N2 - Background and aims of the study: While the hemostatic effect of aprotinin for patients undergoing reoperative coronary bypass is well established, it remains unclear whether these effects extend to patients undergoing reoperative valvular surgery. Methods: We examined our experience with 85 consecutive patients undergoing isolated reoperative valvular surgery with and without use of perioperative aprotinin in order to investigate differences in perioperative blood use, blood loss, bleeding complications, mortality and incidence of myocardial injury. Results: Aprotinin recipients benefitted from a significant reduction in bleeding complications, and a decrease in perioperative and in-hospital mortalities as compared with untreated patients. Anaphylactic reactions and clinically significant thromboembolic events were not observed. There was no difference in the incidence of renal dysfunction or myocardial injury among aprotinin-treated and untreated groups. Conclusions: Our results indicate that aprotinin therapy can be safely administered to patients undergoing reoperative valvular surgery. No increased incidence of anaphylactic reactions, renal dysfunction or perioperative myocardial injury was noted. The observed reductions in bleeding complications and perioperative and in-hospital mortality strongly warrant the evaluation of aprotinin for reoperative valvular surgery in a prospective fashion.

AB - Background and aims of the study: While the hemostatic effect of aprotinin for patients undergoing reoperative coronary bypass is well established, it remains unclear whether these effects extend to patients undergoing reoperative valvular surgery. Methods: We examined our experience with 85 consecutive patients undergoing isolated reoperative valvular surgery with and without use of perioperative aprotinin in order to investigate differences in perioperative blood use, blood loss, bleeding complications, mortality and incidence of myocardial injury. Results: Aprotinin recipients benefitted from a significant reduction in bleeding complications, and a decrease in perioperative and in-hospital mortalities as compared with untreated patients. Anaphylactic reactions and clinically significant thromboembolic events were not observed. There was no difference in the incidence of renal dysfunction or myocardial injury among aprotinin-treated and untreated groups. Conclusions: Our results indicate that aprotinin therapy can be safely administered to patients undergoing reoperative valvular surgery. No increased incidence of anaphylactic reactions, renal dysfunction or perioperative myocardial injury was noted. The observed reductions in bleeding complications and perioperative and in-hospital mortality strongly warrant the evaluation of aprotinin for reoperative valvular surgery in a prospective fashion.

UR - http://www.scopus.com/inward/record.url?scp=0031032453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031032453&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 88

EP - 92

JO - The Journal of heart valve disease

JF - The Journal of heart valve disease

SN - 0966-8519

IS - 1

ER -